A Post-marketing Study to Assess the Safety of Abatacept in Sweden Using the Swedish Rheumatology Quality Register (SRQ) Register

A Nationwide Post-Marketing Study on the Safety of Abatacept Treatment in Sweden Using the SRQ Register

The purpose of this study is to collect real-world data in order to estimate the frequency of overall malignancies, melanoma, basal cell carcinoma, and squamous cell carcinoma in participants with rheumatoid arthritis (RA) or psoriatic arthritis (PsA) enrolled in the SRQ Register in Sweden.

Inclusion Criteria:

• Diagnosis of RA or PsA
• ≥18 years at index treatment initiation
• Participants starting treatment with:
• abatacept
• non-targeted DMARDs
• targeted DMARD

Exclusion Criteria:

- Not applicable